Literature DB >> 31772333

Two new agents target KRAS G12C.

Diana Romero1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31772333     DOI： 10.1038/s41571-019-0304-3

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.

Authors:  Jill Hallin; Lars D Engstrom; Lauren Hargis; Andrew Calinisan; Ruth Aranda; David M Briere; Niranjan Sudhakar; Vickie Bowcut; Brian R Baer; Joshua A Ballard; Michael R Burkard; Jay B Fell; John P Fischer; Guy P Vigers; Yaohua Xue; Sole Gatto; Julio Fernandez-Banet; Adam Pavlicek; Karen Velastagui; Richard C Chao; Jeremy Barton; Mariaelena Pierobon; Elisa Baldelli; Emanuel F Patricoin; Douglas P Cassidy; Matthew A Marx; Igor I Rybkin; Melissa L Johnson; Sai-Hong Ignatius Ou; Piro Lito; Kyriakos P Papadopoulos; Pasi A Jänne; Peter Olson; James G Christensen
Journal:  Cancer Discov       Date:  2019-10-28       Impact factor: 38.272
  1 in total
  6 in total

Review 1.  Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy Efficacy.

Authors:  Gerardo Rosati; Giuseppe Aprile; Alfredo Colombo; Stefano Cordio; Marianna Giampaglia; Alessandro Cappetta; Concetta Maria Porretto; Alfonso De Stefano; Domenico Bilancia; Antonio Avallone
Journal:  Biomedicines       Date:  2022-04-30

2.  Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis.

Authors:  Karen L Reckamp; Tejas Patil; Kedar Kirtane; Thereasa A Rich; Carin R Espenschied; Caroline M Weipert; Victoria M Raymond; Rafael Santana-Davila; Robert C Doebele; Christina S Baik
Journal:  Clin Lung Cancer       Date:  2020-06-20       Impact factor: 4.840

Review 3.  KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block.

Authors:  Juan Esteban Garcia-Robledo; Rafael Rosell; Alejandro Ruíz-Patiño; Carolina Sotelo; Oscar Arrieta; Lucia Zatarain-Barrón; Camila Ordoñez; Elvira Jaller; Leonardo Rojas; Alessandro Russo; Diego de Miguel-Pérez; Christian Rolfo; Andrés F Cardona
Journal:  Ther Adv Respir Dis       Date:  2022 Jan-Dec       Impact factor: 4.031

4.  RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors.

Authors:  Xi Yuan; Zhiyu Tang; Rong Du; Zhan Yao; Shing-Hu Cheung; Xinwen Zhang; Jing Wei; Yuan Zhao; Yunguang Du; Ye Liu; Xiaoxia Hu; Wenfeng Gong; Yong Liu; Yajuan Gao; Zhiyue Huang; Zongfu Cao; Min Wei; Changyou Zhou; Lai Wang; Neal Rosen; Paul D Smith; Lusong Luo
Journal:  Mol Oncol       Date:  2020-05-18       Impact factor: 6.603

5.  Druggable driver gene alterations in redefined large cell carcinoma in Chinese patients: an observational study.

Authors:  Jinhua Yang; Yuping Li; Benting Ma; Huikang Xie; Linsong Chen; Xuejuan Gao; Wenxin He
Journal:  Transl Cancer Res       Date:  2020-12       Impact factor: 1.241

6.  The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer.

Authors:  Shuo Wang; Bethany Woodvine; Vincent van Hoef; Cedric Darini; Nour Ghaddar; Jothilatha Krishnamoorthy; Urszula Kazimierczak; Nicolas Ah-Son; Helmuth Popper; Myriam Johnson; Leah Officer; Ana Teodósio; Massimo Broggini; Koren K Mann; Maria Hatzoglou; Ivan Topisirovic; Ola Larsson; John Le Quesne; Antonis E Koromilas
Journal:  Nat Commun       Date:  2021-07-30       Impact factor: 14.919
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.